Articles tagged with Human Immunodeficiency Virus
Researchers at Scripps Research create a nanodisc platform that preserves key parts of viral surface proteins, allowing for better understanding of antibody interactions. This approach can be applied to other viruses with similar membrane-embedded proteins, such as influenza and SARS-CoV-2.
A new study found that 10-20% of patients who stopped taking daily HIV medication were able to control the virus on their own, thanks to the interaction between antibodies and T cells. The researchers plan to investigate how to strengthen these immune mechanisms to develop a treatment for everyone.
Researchers at Linköping University found that an existing medication can restore immune cell function in people with HIV. The study showed that the medication blocks type I interferon and restored the function of immune cells, potentially improving health outcomes.
A new study reveals two specific genes that act like security locks to keep the virus asleep in some individuals who naturally control HIV even after stopping therapy. Metformin, a common diabetes drug, can activate one of these locks to keep the virus in its dormant state.
Rice bioengineer Omid Veiseh has been awarded a $2.2 million grant to develop implantable cell factory platforms that can deliver therapeutic antibodies over extended periods. The platform aims to reduce dosing frequency and improve access to biologic therapies in low- and middle-income countries.
A York University-led study used machine-learning models to analyze 64 immune biomarkers in people with and without HIV who received COVID-19 vaccines. The researchers found clear vaccine-initiated immune response biomarkers between the two groups, but also identified outliers that provide insights into the complex nature of the immune...
A new tool, HIV-seq, has been developed to profile rare HIV-infected cells from people with HIV. The tool has recovered and analyzed more HIV-infected cells and higher numbers of HIV RNA within those infected cells. The study has identified key differences in people's HIV-infected cells before versus after starting antiretroviral therapy.
A new, daily oral tablet that combines two current HIV treatment medications has shown highly effective control of the HIV virus in a phase 3 clinical trial. Nearly 96% of participants maintained viral control with no new drug resistance reported.
A new daily oral tablet combining bictegravir and lenacapavir (BIC/LEN) was found to be highly effective in maintaining HIV suppression, with nearly 96% of participants who switched to this simplified regimen maintaining viral suppression. The treatment showed similar results compared to complex, multi-pill treatments.
Researchers have successfully isolated and grown authentic reservoir clones (ARCs) that evade the immune system, providing new insights into how to eliminate them. The study suggests that potent CTLs can catch these cells during brief windows of HIV visibility, slowly shrinking the reservoir.
Researchers developed a new single-cell transcriptomic clock called Tictock to measure aging in specific immune cells. The study found that COVID-19 and HIV alter T cell composition and accelerate the biological age of naïve CD8 T cells, while long-term antiretroviral therapy stabilizes T cell proportions.
Scientists at the University of Delaware discovered a previously unknown structural role for the HIV integrase protein, which forms gluey filaments that anchor the RNA genome to the capsid. This discovery provides a promising new target for drug development and could lead to the development of next-generation inhibitors.
Researchers developed antibody–drug conjugates that combine CD4 mimic and neutralizing antibodies to target HIV entry, showing seven times better efficacy than existing approaches. The strategy aims to block HIV before it enters the host cell, offering a more targeted therapeutic profile and potentially reducing adverse effects.
A new study found that tuberculosis is a major cause of deadly sepsis among people living with HIV, particularly in Africa. Early treatment of TB has been shown to significantly reduce sepsis deaths, with a 23% reduction in mortality rate.
Research reveals disparities in access to PrEP among young cisgender females and males, highlighting the need for targeted interventions to improve HIV prevention. The study analyzed data from over 7,000 visits to a Boston-based clinic, finding that only 17% of visits received PrEP for under-age females.
A multinational clinical trial found that the long-term HIV treatment regimen is safe and favored by adolescents who received injectable intramuscular antiviral medications cabotegravir and rilpivirine. The study showed continued viral suppression after 48 weeks with no major safety concerns.
A team at Texas Biomedical Research Institute found that even with effective treatments for TB and HIV, the immune system remains seriously out-of-whack following treatment. The study suggests that host-directed therapies specifically targeting the immune system could potentially restore lung immune system functionality.
A study found that switching to electronic medical records at HIV clinics in Malawi led to a 28% reduction in deaths after five years, with the greatest impact on children. The introduction of EMR systems prevented approximately 5,050 AIDS deaths and improved healthcare efficiency.
Researchers will investigate how HIV and cancer drugs damage brain cells over time, identifying potential early biomarkers of neurotoxicity. They will use human brain organoids grown in the lab to mimic brain physiology.
A new modeling study suggests that regular testing for sexually transmitted infections (STIs) can successfully reduce their spread, even if individuals on PrEP engage in riskier behavior. The paradoxical findings highlight the importance of careful surveillance data interpretation when evaluating public health interventions.
A reduced pledge by Canada to the Global Fund could lead to decreased success in controlling tuberculosis and HIV/AIDS in the country. The authors of an editorial urge Canada's government to invest in improving social determinants of health and implement disease-specific suggestions to address these pressing global health issues.
Experts emphasize powerful therapeutics and successful programs like Global Fund and PEPFAR have saved millions of lives. However, funding pauses led to thousands of deaths, and further action is needed to avoid millions more HIV infections and deaths.
A study from the Ragon Institute of Mass General Brigham, MIT and Harvard found that immune cells called CD8+ T cells play a crucial role in controlling HIV. Researchers discovered that having these CD8+ T cell features before treatment was most important for achieving remission.
Experts Gregory Folkers and Anthony Fauci highlight promising therapeutic developments in antiretroviral treatments for HIV/AIDS. The authors emphasize the need for continued research to end the AIDS epidemic, citing recent advances as unfinished business.
A new combination therapy approach enabled seven out of ten participants to keep the virus at low levels for many months after going off antiretroviral therapy. The results suggest a possible cure for HIV and offer a proof of concept that this approach could work.
A study found that hepatitis C treatment with direct-acting antivirals (DAAs) improves immune function in individuals co-infected with HIV and HCV, even in those with advanced liver disease. The treatment resulted in significant declines in inflammation and liver damage markers.
Research at Amsterdam UMC found that early HIV treatment improves immune system function in the short term but leads to dysregulation in the long term. After six months of treatment, the immune system functions similarly to that of people without HIV, but this improvement is temporary and does not last beyond three years.
A new study from Texas Biomedical Research Institute found that low-dose THC significantly reduced side effects and inflammation caused by HIV and antiretroviral therapy. The treatment also increased serotonin levels, lowered cholesterol and toxic bile acids, and improved cardiovascular health.
A new study finds that people living with HIV experience higher rates of sleep issues even when virally suppressed, associated with a higher risk for heart disease, depression, and cognitive decline. The study highlights the importance of treating healthy sleep as a fundamental health right, not a luxury.
A new study by Alana Rojewski and Katherine Sterba aims to improve access to tobacco cessation treatments for people living with HIV who smoke. The ENHANCE-TTS program will train pharmacists as tobacco treatment specialists and tailor-design programs for each clinic, taking into consideration the unique needs of the local population.
A new UCLA study reveals that breast milk from women living with HIV contains significantly lower levels of tryptophan, an essential amino acid important for infant immune function and brain development. The study suggests that this depletion may be a common denominator explaining the immune, growth, and cognitive differences seen in c...
Salk Institute researchers have determined the structure of HIV's integrase protein during its newly discovered function, enabling the development of better HIV therapeutics. The study reveals a surprising flexibility in the protein's architecture, which can interact with both DNA and RNA, paving the way for new integrase-targeting drugs.
A team of UCF researchers is creating a single low-cost test to detect multiple viruses simultaneously, which may be used in resource-limited settings. The test has the potential to save lives by providing quicker and more accessible results.
A study published in The Lancet Primary Care found that older adults with HIV are more likely to receive opioids and experience opioid use disorder compared to those without HIV. This disparity highlights the need for tailored strategies to safely prescribe opioids and expand access to treatment.
A new research project, STREAMS, aims to improve mental health and antiretroviral treatment adherence among adolescents living with HIV in rural Uganda. The study will evaluate the effectiveness of a novel intervention combining mobile technology, economic empowerment, and medication support.
A successful HIV vaccine could be a major public health breakthrough, preventing 1.3 million new infections in 2024 and saving lives from the virus. The new childhood vaccine is based on the Env trimer protein complex and aims to elicit broadly neutralizing antibodies in young immune systems.
The new guidelines, published in Infection Control & Hospital Epidemiology, provide evidence-based guidance for healthcare personnel following occupational exposures to HIV. The recommendations emphasize the importance of prompt evaluation and initiation of postexposure prophylaxis (PEP), while streamlining follow-up protocols.
Even modest reductions in PrEP coverage result in thousands of avoidable HIV infections. The study estimates billions of dollars in increases in net health care costs due to these reductions.
Researchers at UAB have published a study suggesting one dose of benzathine penicillin G is as effective as the three-injection regimen at treating early syphilis. The study found that one dose is sufficient to treat patients, reducing time and inconvenience associated with multiple injections.
A scientific team co-led by Dr. Lishomwa Ndhlovu at Weill Cornell Medicine has received an NIH MERIT Award to study a handful of people who have managed to clear HIV after a stem cell transplant. The goal is to identify the immune mechanisms that led to remission and develop a broadly applicable immunotherapy for eliminating HIV.
A new HIV antiretroviral compound, MK-8527, has demonstrated robust antiviral activity and pharmacokinetics in animal studies. The lead compound is a novel inhibitor of HIV reverse transcriptase translocation with potential for extended-duration dosing.
A big data study using multi-omics data from over 1,300 people with HIV has identified key molecular players causing non-AIDS-related comorbidities. The research reveals a range of previously hidden molecular patterns and players associated with various comorbidities.
Researchers have developed a stable Env protein trimer, SOSIP.664, that can elicit broadly neutralizing antibodies against HIV. The breakthrough came after decades of work and multiple modifications to the protein, which is harder to engineer than its counterpart on SARS-CoV-2.
Weill Cornell Medicine leads a $14.9M NIH grant program to remove latent HIV from cells, aiming for effective cures. Researchers will use a personalized approach to develop tailored immunotherapies and broadly neutralizing antibodies against HIV.
Researchers found that children unexposed to HIV had higher taxonomic turnover in their oral microbiomes, indicating less adaptability to environmental changes. Children living with HIV had more stable oral microbiomes and higher frequencies of cavity-causing bacteria.
Researchers from Kumamoto University identified a genetic 'silencer' element that keeps the human T-cell leukemia virus type 1 (HTLV-1) in a dormant state, evading immune detection. This discovery offers hope for new therapeutic approaches to treat HTLV-1 and potentially even HIV.
A new gene therapy strategy has shown multi-year protection from HIV/AIDS infection in newborns via broadly neutralizing antibodies. The treatment, administered once at birth, could prevent HIV-1 transmission during breastfeeding, especially in areas where access to antiretroviral medications is limited.
Researchers developed an AI tool to automatically generate HIV prevention and testing campaign messages for counties in the US, leveraging real-time social media data. The method was tested in three studies, showing that AI-selected messages were perceived as more actionable and effective by target audiences than control messages.
Researchers investigated the link between HIV treatment regimens and osteoarthritis development, revealing that certain medications like lopinavir can exacerbate OA in the knee. The study's findings have important implications for people living with HIV, highlighting the need to carefully consider treatment options.
The study found that HIV testing rates were higher among men, younger individuals, and migrants, while women, older adults, and those living in rural areas were underdiagnosed. The results also reveal significant differences by socioeconomic level and geographical area, highlighting the need for targeted interventions to improve adhere...
Researchers at Tulane University developed a handheld TB test inspired by the bombardier beetle's natural defense mechanism. The ASTRA device requires only a drop of blood and delivers same-day diagnoses without need for laboratory or trained staff, outperforming traditional tests in detection of TB with HIV co-infection.
Researchers at MIT and Scripps Research Institute developed a vaccine that generates many more HIV-targeting B cells in mice with just one dose, using two adjuvants. The dual-adjuvant vaccine produces a wider diversity of antibodies against an HIV antigen, allowing the immune system to build up a stronger response.
A daily dose of trimethoprim-sulfamethoxazole reduced the proportion of preterm births by 40% in pregnant women with HIV. The antibiotic also increased birth weight by 177 grams, improving health outcomes for babies. Researchers hope to confirm these findings in future trials.
Researchers at Scripps Research Institute have made a breakthrough in creating an effective HIV vaccine by developing a two-step vaccination strategy that induces powerful broadly neutralizing antibodies. The approach successfully blocked nearly 70% of HIV strains, including those typically hard to target.
The US Department of Health and Human Services Panel has recommended moderate-intensity statin therapy as the primary prevention among adults with HIV aged 40-75 years with low to intermediate 10-year atherosclerotic cardiovascular disease (ASCVD) risk. For those with a 10-year ASCVD risk score of 5% or higher, statin therapy is strong...
A new study found that eight times more American young adults now take HIV-prevention medication than a decade ago, but inconsistent use and barriers persist. PrEP can reduce the chances of acquiring HIV by 99%, emphasizing the need for healthcare providers and public health agencies to promote consistent use among high-risk patients.
A new study finds connections between extreme weather events and HIV vulnerabilities, including increased transactional sex, reduced condom agency, and LGBTQ stigma. Researchers studied 21 sex workers and 15 gbMSM in Nairobi, Kenya, revealing interrelated links between climate change-related resource insecurities and HIV risk.
A new study finds that cannabis use disorder diagnoses rose substantially across all age groups, race/ethnicity, and comorbidity subgroups nationwide from 2000 to 2022. People living with HIV experienced the greatest relative increase in CUD diagnoses, particularly among older adults.
Researchers from Amsterdam UMC have made a breakthrough in developing an HIV vaccine with a germline-targeting strategy, inducing immune responses in participants. The phase one trial showed promising results, suggesting the potential for this approach to be further developed into a vaccine.
Two phase 1 clinical trials demonstrate the success of a targeted vaccine strategy in activating early immune responses relevant to HIV and advancing them further. The trials provide evidence for a stepwise approach to elicit custom-tailored responses and validate the rational vaccine design underlying this approach.